Immunotherapy, which was first trialled on hay fever patients in London in 1911, has an excellent record in helping reduce allergy symptoms. But how long it works after treatment stops seems to depend of how long patients receive the therapy, which involves increasing exposure to grass pollen over time. This is the conclusion of researchers at Imperial College, London, who have found that immunotherapy could markedly reduce symptoms for several years after a three-year course of treatment, but not after two years of treatment, when the benefits quickly waned.
Previous research has shown that a type of immunotherapy that exposes patients to increasing amounts of grass pollen over time is an effective way to reduce severe symptoms in the long term.The research, published in the latest issue of the journal JAMA was funded by the Immune Tolerance Network, supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA.
“You treat patients for three years and then they have a big improvement in their hay fever for several years afterwards,” said Professor Stephen Durham, Head of Allergy and Clinical Immunology at the National Heart and Lung Institute at Imperial and clinical lead for allergy services at Royal Brompton Hospital, who led the study.
“Exposing people to grass pollen in this way is a very effective treatment for people who really have debilitating hay fever.”
Hay fever, or seasonal allergic rhinitis, affects as many as one in four people in the UK, leaving sufferers with bouts of sneezing, runny nose and itchy eyes – all of which can affect work, school and leisure during the summer months when the pollen count soars.
In the majority of cases in the UK the culprit is grass pollen, which the body recognises as an invader, launching an immune response.
A number of over the counter medications are available, such as nasal sprays and antihistamine tablets, but patients with more severe symptoms can be treated with immunotherapy, using a similar approach to the one trialled in children with peanut allergies.
By exposing their immune system to grass pollen extracts over time they are able to build up their resistance, either through injections or a pill containing pollen extract.
The latest study involved patient volunteers at Royal Brompton Hospital in London, which runs a world-class allergy clinic, researchers tested the effectiveness of two immunotherapies prescribed by the NHS which use grass pollen extract: an injection and a pill taken under the tongue.
It was the first head to head trial of the two therapies, in which researchers set out to see if a two-year treatment could achieve the same long-lasting benefits to patients as seen with three-years of immunotherapy, potentially leading to clinical cost savings.
The study was a double blind, placebo-controlled trial in which 106 patients were randomised to one of three treatment groups: injection, tablets and placebo.
Patients had moderate to severe hay fever and were administered either the daily oral treatment, weekly injections for 15 weeks followed by monthly boosters, or a placebo. A total of 92 patients completed the study.
After a two year course of treatment, the results showed that both therapies were effective at tackling symptoms, with patients reporting a dramatic improvement in their quality of life. However, one year after patients had stopped taking the medication the effects were no better than the placebo group.
“Hay fever causes major impairment of sleep, work and school performance and leisure activities during what for most of us is the best time of the year,” said Professor Durham.
“Most people respond to the usual antihistamines and nasal sprays, although there is a portion who do not respond adequately or who have unacceptable side effects to the treatment.”
Describing the current findings, Professor Durham said: “This study shows that whereas both immunotherapy treatments were highly effective, two years of treatment was insufficient for long-term benefits.
“Clinicians and patients should continue to follow international guidelines that recommend a minimum of three years’ treatment.”
Previous studies published by Imperial researchers have shown the long-lasting benefits of both immunotherapy injections and pills for severe hay fever – benefits which persist for at least two to three years after the treatment has stopped.
Professor Durham added: “We have reconfirmed that both treatments are effective but that in order to get the long-term clinical benefits after stopping the treatment, you have to take it for three years.”
 logo final copy.png)
- New study challenges social media’s mental health impact - 21st November 2024
- Do Finland introduces a new care pathway for epilepsy - 21st November 2024
- Innovative swim program for people with cerebral palsy - 21st November 2024
